Israel 21c predicts that’s Nyxoah’s leadless and minimally invasive neurostimulator for treating sleep apnea will disrupt healthcare.
The company is now gathering additional clinical evidence on Genio, initiating European market development and working toward FDA approval.
OSA is the most common form of sleep apnea, a condition estimated to affect at least 100 million people worldwide.
